Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.fatetherapeutics.com
Fate Therapeutics, Inc. News Releases
Get the latest updates from Fate Therapeutics, Inc. News Releases directly as they happen.
Follow now 65 followers
Latest posts
Last updated 4 days ago
Fate Therapeutics to Present at Upcoming Investor Conferences
4 days ago
SAN DIEGO , Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
16 days ago
First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
23 days ago
SAN DIEGO , Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
about 2 months ago
SAN DIEGO , July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
3 months ago
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe...
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
3 months ago
SAN DIEGO , May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
3 months ago
Oral presentation of clinical data from FT819 Phase 1 study highlights safety...
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
3 months ago
Oral presentation of clinical data from FT819 Phase 1 study highlights safety...
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
4 months ago
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in...
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
4 months ago
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
4 months ago
SAN DIEGO , May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc...
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
4 months ago
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products...